Immix Biopharma, Inc. (IMMX)

Immix Biopharma Statistics

Total Valuation

Immix Biopharma has a market cap or net worth of $67.62 million. The enterprise value is $57.68 million.

Market Cap	67.62M
Enterprise Value	57.68M

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025, after market close.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Immix Biopharma has 32.67 million shares outstanding. The number of shares has increased by 25.52% in one year.

Current Share Class	32.67M
Shares Outstanding	32.67M
Shares Change (YoY)	+25.52%
Shares Change (QoQ)	+0.95%
Owned by Insiders (%)	17.98%
Owned by Institutions (%)	11.16%
Float	22.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	12.76
P/TBV Ratio	14.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.22.

Current Ratio	1.23
Quick Ratio	1.16
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -162.04% and return on invested capital (ROIC) is -96.90%.

Return on Equity (ROE)	-162.04%
Return on Assets (ROA)	-66.85%
Return on Invested Capital (ROIC)	-96.90%
Return on Capital Employed (ROCE)	-422.78%
Revenue Per Employee	n/a
Profits Per Employee	-$1.10M
Employee Count	21
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Immix Biopharma has paid $40,665 in taxes.

Income Tax	40,665
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.83% in the last 52 weeks. The beta is 0.25, so Immix Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.25
52-Week Price Change	+11.83%
50-Day Moving Average	2.46
200-Day Moving Average	2.12
Relative Strength Index (RSI)	41.47
Average Volume (20 Days)	183,048

Short Selling Information

The latest short interest is 369,043, so 1.13% of the outstanding shares have been sold short.

Short Interest	369,043
Short Previous Month	122,600
Short % of Shares Out	1.13%
Short % of Float	1.61%
Short Ratio (days to cover)	1.42

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-23.78M
Pretax Income	-18.18M
Net Income	-23.13M
EBITDA	-23.66M
EBIT	-23.78M
Earnings Per Share (EPS)	-$0.78

Balance Sheet

The company has $11.64 million in cash and $1.04 million in debt, giving a net cash position of $10.60 million or $0.32 per share.

Cash & Cash Equivalents	11.64M
Total Debt	1.04M
Net Cash	10.60M
Net Cash Per Share	$0.32
Equity (Book Value)	4.65M
Book Value Per Share	0.16
Working Capital	2.32M

Cash Flow

In the last 12 months, operating cash flow was -$12.51 million and capital expenditures -$974,036, giving a free cash flow of -$13.48 million.

Operating Cash Flow	-12.51M
Capital Expenditures	-974,036
Free Cash Flow	-13.48M
FCF Per Share	-$0.41

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immix Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-25.52%
Shareholder Yield	-25.52%
Earnings Yield	-33.87%
FCF Yield	-19.75%

Analyst Forecast

The average price target for Immix Biopharma is $8.00, which is 286.47% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.00
Price Target Difference	286.47%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1